Abvc Biopharma (ABVC) Cash from Financing Activities (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Cash from Financing Activities came in at -$342181.0 in Q1 2026, down 179.81% YoY from $428756.0 in Q1 2025, and down 131.74% on a QoQ basis from $1.1 million in Q4 2025.
Abvc Biopharma (ABVC) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 16 years of Cash from Financing Activities data on file, last reported at -$342181.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 179.81% year-over-year to -$342181.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (up 160.34% YoY) and the FY2025 annual result came in at $4.6 million, up 134.15% from the prior year.
- Cash from Financing Activities slipped to -$342181.0 in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $2.2 million in Q1 2023 to a low of -$342181.0 in Q1 2026.
- A 5-year average of $699769.6 and a median of $603500.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities jumped 2639.51% — and 2026, when it plunged 179.81%.
- Tracing ABVC's Cash from Financing Activities over 5 years: stood at -$253500.0 in 2022, then jumped by 115.16% to $38421.0 in 2023, then jumped by 774.06% to $335822.0 in 2024, then soared by 221.02% to $1.1 million in 2025, then slumped by 131.74% to -$342181.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$342181.0 (Q1 2026), $1.1 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | 226,209.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 226,209.00 |
| Jun 30, 2026 | 226,209.00 |
| Mar 31, 2026 | -342,181.00 |
| Mar 31, 2026 | -342,181.00 |
| Dec 31, 2025 | 1.08 Mn |
| Dec 31, 2025 | 1.08 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | 1.93 Mn |
| Mar 31, 2025 | 428,756.00 |
| Mar 31, 2025 | 428,756.00 |
| Dec 31, 2024 | 335,822.00 |
| Dec 31, 2024 | 335,822.00 |
| Sep 30, 2024 | -81,356.00 |
| Sep 30, 2024 | -81,356.00 |
| Jun 30, 2024 | 802,156.00 |
| Jun 30, 2024 | 802,156.00 |
| Mar 31, 2024 | 924,147.00 |
| Mar 31, 2024 | 924,147.00 |